Search
Zhifei Biologics Receives Approval for Clinical Trials of Recombinant Varicella Zoster Vaccine
3 week ago /
Read about 0 minute
Author：小编
The National Medical Products Administration has granted approval for clinical trials of a recombinant varicella zoster vaccine developed by Zhifei Biologics' wholly-owned subsidiary. Targeted at individuals aged 40 and above, this vaccine aims to prevent herpes zoster. Utilizing an independently developed adjuvant system, the vaccine is anticipated to enhance its preventive efficacy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
